期刊文献+

早期护理干预对ET新辅助化疗不良反应的影响

下载PDF
导出
摘要 目的观察使用ET(表阿霉素+多西紫杉醇)新辅助化疗方案治疗的乳腺癌患者的不良反应发生率,探讨在后续化疗早期采取相应护理措施干预能否减少不良反应发生率。方法观察我科2004年1月至2007年11月接受ET(表阿霉素+多西紫杉醇)方案化疗的64例乳腺癌患者第1周期化疗期间的不良反应发生率,而后在后续化疗进行早期干预,研究早期护理干预对化疗不良反应发生率的影响。结果经过早期护理干预,新辅助化疗的不良反应率中,血小板减少、腹泻、心脏毒性、肌痛、外周性水肿等无显著差异,中性粒细胞缺乏、乏力、恶心、呕吐经早期干预后发生率降低(P<0.05)。结论ET方案新辅助化疗期间采取良好而有针对性的早期护理干预措施,可以减轻患者的痛苦经验,使其顺利完成化疗。
出处 《海南医学》 CAS 2009年第9期162-164,共3页 Hainan Medical Journal
  • 相关文献

参考文献3

二级参考文献11

  • 1Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res,1989,49:1996-2001.
  • 2Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1979,63:1727-1733.
  • 3Fisher B,Bryant J,Wolmark N,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol,1998,16: 2672-2685.
  • 4Gardin G, Rosso R, Campora E,et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer, 1995,31A: 1428-1433.
  • 5Chen SC, Chang HK, Lin YC, et al. Neoadjuvant chemotherapy with biweekly epirubicin and paclitaxel for locally advanced breast cancer. Proc Am Soc Clin Oncol, 2003,22:58.
  • 6Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary chemotherapy with doxeorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol, 1997, 24(5 suppl 17): S17-10-S17-14.
  • 7Ezzat AA, Rahal M, Ajarim D, et al. Dose-dense neoadjuvant sequential chemotherapy in the management of locally advanced breast cancer: a phase Ⅱ study. Pro Am Soc Clin Oncol, 2003,22:51.
  • 8Milla A, Morales S, Burillo MA, et al. High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC): an ONCOPAZ and associated hospitals study. Breast Cancer Res Treat, 2001,69:271.
  • 9Wachters B, Annemie P, Ines D, et al. Efficacy and tolerance of epirubicin docetaxel (E-T) in patients with inflammatory breast caner (IBC). Breast Cancer Res Treat, 2001,69:301.
  • 10Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclinecontaining chemotherapy. J Clin Oncol, 1999, 17: 1413-1424.

共引文献57

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部